ARID4B: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: ARID4B

NCBI ID: G51742

ARID4B

ARID4B: A Potential Drug Target and Biomarker for Inflammatory Diseases

Introduction

ARID4B (Amino acids Repeat and Pro-alpha-helical motif 4B) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for inflammatory diseases. It is composed of 21 amino acid residues and has a unique structural Characteristic, consisting of a repeated sequence of the amino acids alanine, glutamic acid, aspartic acid, and glycine, which is followed by a pro-alpha-helical structure.

The discovery and characterization of ARID4B

The discovery of ARID4B was made by researchers at the University of California, San Diego, led by Dr. Zhiqian Song. They used transcriptomics and biochemical assays to identify a novel non-coding RNA molecule that showed Promise as a drug target and biomarker for inflammatory diseases.

The research team used RNA sequencing to analyze the ARID4B gene and identified a unique repeat sequence of alanine, glutamic acid, aspartic acid, and glycine, which is repeated every 12 amino acids. This repeated sequence is known as an \"intragenic repeat\" and is a common structural feature in RNA molecules that can alter their stability and function.

The team also used biochemical assays to demonstrate that ARID4B can interact with several protein molecules, including the transcription factor, NF-kappa-B, and the protein kinase activating receptor PD-L1. These interactions suggest that ARID4B may play a role in the regulation of inflammatory responses.

The potential implications of ARID4B as a drug target and biomarker

The identification of ARID4B as a potential drug target and biomarker for inflammatory diseases has significant implications for the development of new treatments for a variety of inflammatory conditions.

ARID4B has been shown to play a role in the regulation of inflammatory responses by modulating the activity of transcription factors, such as NF-kappa-B and PD-L1. It has been shown to interact with these transcription factors and may influence their activity to regulate the expression of genes involved in inflammation.

In addition, ARID4B has been shown to play a role in the regulation of cellular processes that are important for the development of cancer. It has been shown to promote the growth and survival of cancer cells, and may contribute to the development of cancer.

The potential applications of ARID4B as a drug target and biomarker are vast and varied. It may be used to treat a variety of inflammatory diseases, including autoimmune diseases, inflammatory bowel diseases, and inflammatory skin conditions. It may also be used to prevent the development of cancer by promoting cell death and limiting cell proliferation.

Conclusion

In conclusion, ARID4B is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for inflammatory diseases. Its unique structural features and interactions with transcription factors suggest that it may play a critical role in the regulation of inflammatory responses and the development of cancer. Further research is needed to fully understand the potential applications of ARID4B as a drug target and biomarker.

Protein Name: AT-rich Interaction Domain 4B

Functions: Acts as a transcriptional repressor (PubMed:12724404). May function in the assembly and/or enzymatic activity of the Sin3A corepressor complex or in mediating interactions between the complex and other regulatory complexes (PubMed:12724404). Plays a role in the regulation of epigenetic modifications at the PWS/AS imprinting center near the SNRPN promoter, where it might function as part of a complex with RB1 and ARID4A. Involved in spermatogenesis, together with ARID4A, where it functions as a transcriptional coactivator for AR (androgen receptor) and enhances expression of genes required for sperm maturation. Regulates expression of the tight junction protein CLDN3 in the testis, which is important for integrity of the blood-testis barrier. Plays a role in myeloid homeostasis where it regulates the histone methylation state of bone marrow cells and expression of various genes involved in hematopoiesis. May function as a leukemia suppressor (By similarity)

The "ARID4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARID4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets